| Wissenschaftl. Titel | A Phase III, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Giredestrant in Combination With Phesgo Versus Phesgo After Induction Therapy With Phesgo + Taxane in Patients With Previously Untreated HER2-Positive, Estrogen Receptor-Positive Locally-Advanced or Metastatic Breast Cancer |
| Erkrankung |
Gyn:
Mamma-Ca:
Erstlinie
|
| Molekularer Marker |
ER+ HER2+ |
| Kurzprotokoll | Kurzprotokoll |
| Links | Weiterführende Informationen (HD) Weiterführende Informationen (NIH) |
erstellt 18.09.2024 Data entry III CCP
geändert 18.09.2024 Data entry III CCP